Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tyra Biosciences, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
TYRA
Nasdaq
2830
tyra.bio
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tyra Biosciences, Inc.
Tyra Biosciences to Present at Upcoming Investor Conferences
- Feb 11th, 2025 9:05 pm
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
- Jan 29th, 2025 9:05 pm
Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33%
- Jan 27th, 2025 1:53 pm
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
- Jan 22nd, 2025 1:00 pm
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
- Jan 10th, 2025 1:00 pm
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate
- Nov 30th, 2024 2:58 pm
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Nov 7th, 2024 9:05 pm
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
- Nov 3rd, 2024 1:45 pm
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
- Oct 28th, 2024 11:00 am
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- Oct 24th, 2024 10:05 pm
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
- Oct 23rd, 2024 8:05 pm
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
- Oct 20th, 2024 1:00 pm
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
- Oct 18th, 2024 6:34 pm
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc
- Oct 16th, 2024 5:01 am
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
- Oct 11th, 2024 12:00 pm
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
- Sep 11th, 2024 8:05 pm
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
- Sep 10th, 2024 8:05 pm
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet
- Sep 9th, 2024 1:55 pm
Tyra Biosciences, Inc. (TYRA): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
- Aug 27th, 2024 11:50 pm
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
- Aug 7th, 2024 8:05 pm
Scroll